On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
Authors
Keywords
-
Journal
ONCOGENE
Volume 32, Issue 11, Pages 1341-1350
Publisher
Springer Nature
Online
2012-05-14
DOI
10.1038/onc.2012.164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas
- (2017) M. N. Saleh et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).
- (2017) C. S. Karapetis et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
- (2017) J. Von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- FLIPLinduces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity
- (2011) Cristina Pop et al. BIOCHEMICAL JOURNAL
- Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents
- (2011) C. Menke et al. CANCER RESEARCH
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
- (2011) J. Lu et al. MOLECULAR CANCER THERAPEUTICS
- Enhanced Anticancer Effect of the Combination of Cisplatin and TRAIL in Triple-Negative Breast Tumor Cells
- (2011) L. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
- (2011) Andrew Oberst et al. NATURE
- TRAIL Receptor Signaling Regulation of Chemosensitivity In Vivo but Not In Vitro
- (2011) Christina Menke et al. PLoS One
- Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
- (2011) C R Reis et al. Cell Death & Disease
- In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide
- (2010) Andrew E. Logan et al. APOPTOSIS
- Death Receptor Agonists as a Targeted Therapy for Cancer
- (2010) J. Wiezorek et al. CLINICAL CANCER RESEARCH
- Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
- (2010) H. M. Stern et al. CLINICAL CANCER RESEARCH
- Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
- (2010) L. Zhang et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- TRAIL receptor signaling and therapeutics
- (2010) Junaid Abdulghani et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Overcoming TRAIL resistance in ovarian carcinoma
- (2010) Kerri S. Bevis et al. GYNECOLOGIC ONCOLOGY
- Inducible Dimerization and Inducible Cleavage Reveal a Requirement for Both Processes in Caspase-8 Activation
- (2010) Andrew Oberst et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma
- (2010) Bernhard Gillissen et al. JOURNAL OF CELL BIOLOGY
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers
- (2010) J S Imam et al. ONCOGENE
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- LY303511 Enhances TRAIL Sensitivity of SHEP-1 Neuroblastoma Cells via Hydrogen Peroxide-Mediated Mitogen-Activated Protein Kinase Activation and Up-regulation of Death Receptors
- (2009) K. Shenoy et al. CANCER RESEARCH
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
- (2009) Tae-Jin Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition
- (2009) Erica L. McCoy et al. JOURNAL OF CLINICAL INVESTIGATION
- The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling
- (2009) Douglas S. Micalizzi et al. JOURNAL OF CLINICAL INVESTIGATION
- Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
- (2009) John Yee et al. JOURNAL OF CLINICAL ONCOLOGY
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins
- (2009) Henrick Horita et al. JOURNAL OF NEURO-ONCOLOGY
- TRAILing death in cancer
- (2009) Gregory Mellier et al. MOLECULAR ASPECTS OF MEDICINE
- Six1 Overexpression in Mammary Cells Induces Genomic Instability and Is Sufficient for Malignant Transformation
- (2008) R. D. Coletta et al. CANCER RESEARCH
- Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis
- (2008) P Makhov et al. CELL DEATH AND DIFFERENTIATION
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
- (2008) D Ross Camidge EXPERT OPINION ON BIOLOGICAL THERAPY
- ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
- (2008) Jin H. Song et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPSdown-regulation
- (2008) Jin Yeop Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- FLIP as an Anti-Cancer Therapeutic Target
- (2008) Jin Kuk Yang YONSEI MEDICAL JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started